Jeffrey Miller, MS, a health economist with nearly 20 years of professional experience, joined RTI Health Solutions as Executive Director of Health Economics. He is based in our
Jeffrey brings considerable technical expertise in designing and conducting economic evaluations of pharmaceuticals, medical devices, diagnostic products, and health-related environmental regulatory programs.
He is a specialist in health economic modeling and other pharmacoeconomic decision-analytics, including cost-of-illness models, cost-effectiveness/cost-utility models, and budget-impact models in multiple therapeutic areas. Additionally, his past work and expertise includes the development of product value messaging and navigating pharmaceutical pricing and reimbursement hurdles in the U.S. and global healthcare markets.
Previously, he held several scientific positions with increasing responsibility at Abt Bio-Pharma Solutions, Boston Health Economics, and Medical Research International.
Mr. Miller holds a B.A. in Economics and English Literature from Keene State College, Keene, NH, and a M.S. in Resource Economics from the University of New Hampshire, Durham, NH.
Jeffrey has published within multiple therapeutic areas, including cancer, cardiovascular disease, hypertension, thrombosis, pain/analgesia, arthritis, and pulmonary disease.
"I am very excited to join RTI-HS,” Miller said. “The caliber of the staff and research produced at RTI-HS are second to none. RTI-HS is well-positioned in the health economics and outcomes research space, and I look forward to contributing to the success of the organization.”
About RTI Health Solutions
RTI Health Solutions provides scientifically rigorous research and consulting services in health economics, patient-reported outcomes, regulatory and health outcomes strategy, market access, health preference assessment, epidemiology, biostatistics, drug safety and pharmacovigilance, preclinical and clinical development to help biopharmaceutical companies successfully develop and gain market approval for their products.